The persistence of humoral and cellular immunity to varicella-zoster virus (VZV) was evaluated in 60 children and 18 adults immunized with live attenuated VZV vaccine. At a mean of 5 years after vaccination, 93% of children and 94% of adults had IgG antibodies to VZV as determined by ELISA. VZV antibody concentrations were significantly higher at 5 years than at 1 year after immunization in children and adults. Cell-mediated immunity to VZV was detected in 87% of children and 94% of adults at 5 years. The mean stimulation index was significantly higher at 5 years than at 1 year among children and adults. Cytokine responses to VZV, including interleukin-2, interferon-g, and interleukin-10 were equivalent between children and adults at 5 years. In summary, varicella immunization induced long-term humoral and cellular immunity, and initial differences between cell-mediated responses in children and adults diminished over time.
Immunization with the live attenuated varicella vaccine elicresponses, which are important for the resolution of VZV infection and maintenance of latency [1] . Natural immunity is charits protection against varicella-zoster virus (VZV), a human herpesvirus that causes varicella (chickenpox) and reactivates acterized by the long-term persistence of circulating T cells that recognize VZV proteins and by the persistence of IgG as herpes zoster (shingles) [1] . The varicella vaccine was developed and evaluated in clinical trials in Japan in the 1970s [2] .
antibodies to VZV. After natural infection, cellular immunity to VZV, measured In the United States, clinical trials were conducted in children with leukemia and later in healthy children [3] . The varicella as in vitro T cell proliferation, is well-preserved until the fifth decade of life or later. An age-related decline in cellular immuvaccine elicits humoral and cellular immunity in children and adults [4, 5] . Early vaccine studies demonstrated an age-related nity to VZV then occurs, which predisposes to herpes zoster. VZV-specific T lymphocytes are found in CD4 / and CD8 / difference in seroconversion rates, resulting in the recommendation of a two-dose regimen for adolescents and adults [6, subsets. Within the CD4 / subset, T cells that recognize VZV protein are predominately of the Th1 CD4 / subset, producing 7]. Whether the initial administration of the varicella vaccine induces prolonged immunity or whether revaccination will be interleukin (IL)-2 and interferon (IFN)-g [11] . Cytokine profiles of elderly immune persons demonstrate that Th1 type needed is an important question.
The vaccine, produced by Merck (West Point, PA), is made CD4 / T cell function declines significantly with age, whereas Th2 type responses, detected by IL-4 production, do not [11] . from the Oka isolate of VZV; it is produced in human diploid cells and given as a subcutaneous inoculation. Clinical attenuaThus, induction and preservation of Th1 CD4 / T cell immunity appears to represent the optimal response to VZV. tion of this vaccine has been shown in pre-and postlicensure experience [2, 8, 9] . Our analysis of the virologic basis of The purpose of this study was to assess the long-term persistence of cellular immunity compared with that of VZV IgG attenuation demonstrates that it results from impaired replication in epidermal and dermal cells [10] .
antibodies in immunized children and adults and to characterize the relative preservation of Th1 and Th2 type cytokine reThe host response to primary infection with VZV involves synchronous induction of humoral and cell-mediated immune sponses. for both adults and children (P õ .05). Antibody levels were adults had cellular immunity to VZV. At 5 years, VZV-specific [12] . Initial sera were retested in parallel with follow-up sera to index (SI), which is the ratio of mean counts per minute in antigenstimulated wells to that in control-stimulated wells. A positive response was defined as an SI of §3.0. The method used to prepare antigen batches has been standardized to minimize variability between preparations; the antigenicity of each preparation is evaluated using naturally immune subjects.
Patients, Materials, and Methods
Assays for cytokine production. Cytokine release by PBMC was evaluated by stimulation with VZV antigen or uninfected cell control; maximum release in supernatants harvested on days 1-8 was determined. IL-2 was detected using kits from Genzyme (Cambridge, MA); IL-10 and IFN-g were detected using kits from Endogen (Cambridge, MA). Cytokine concentrations were determined using a series of standards and extrapolated from a standard curve. Sensitivities of detection were defined by reference standards in each assay.
Exposure surveys. Five (8.3%) of 60 children and 1 (6%) of 18 adults reported a household exposure to VZV since vaccination. Nine children (15%) and 3 (17%) adults reported a nonhousehold, close-contact exposure that lasted ú4 h.
Statistical analysis. Statistical analyses were done using a computer software program (Microsoft Excel, version 5.0; Microsoft, Redmond, WA). Comparisons were made using Student's paired and unpaired t tests.
Results
Study population. 60 children and 18 adults were reevaluated in our follow-up study. Fifteen of 60 children (25%) and all adults received two doses of vaccine. For children, the mean interval after vaccination was 6.4 years (range, 2.1 -8.4) and for adults was 4.7 years (range, 3.6 -6.2). The mean age at vaccination was 5 years (range, 2 -12) for children and 34 years (range, 23 -43) for adults. The mean SI { SE at day 42 was significantly greater in children than in adults (15.59 { 3.67 vs. 7.19 { 0.95; P Å .03). The mean SI was equivalent at 3 months, by which time, all adults had received two doses of vaccine. Responses diminished in both groups between 3 months and 1 year after vaccination (P Å .13 and .02 for children and adults, respectively). The SIs in individual vaccinees increased significantly between 1 year and the follow-up specimen (P Å .04 for both children and adults) ( figure 1B) .
No statistically significant association between the infectious virus content of the vaccine and the persistence of T cell recognition of VZV antigen was demonstrated.
Cytokine profiles. Cytokine release profiles of proliferating T cells were evaluated when follow-up blood sampling was done. The value in picograms per milliliter was calculated as the difference between the response to the VZV antigen and lower [5] . In our experience with longer follow-up, cell-mediated immunity was found to increase significantly in children cultures from 60% (30/50) of children and 38% (6/16) of adults (figure 2). Background levels (mean concentrations in controland adults, with the responses of adults becoming equivalent to those of children with vaccine-induced immunity. stimulated wells) are given in figure 2. The concentrations of cytokines produced in PBMC cultures for children and adults Consistent with the significant role of the cell-mediated immune response to varicella, VZV infection elicits the proliferawere equivalent and did not correlate with the SI. tion of T cells that produce predominantly Th1 type cytokines [4] . A prominent IFN-g response is characteristic of naturally Discussion acquired immunity to VZV [11] . In our follow-up study, the protection elicited by immunization with live attenuated variIn our study, antibodies to VZV were well-preserved at a mean of 5 years following vaccination in adults and children. cella vaccine was characterized by antigen-specific IL-2 and IFN-g release by activated T cells. No age-related differences Similarly high rates of antibody persistence have been observed in healthy children; surveillance studies have demonstrated that in the cytokine secretion patterns of cultured T cells were detected with long-term follow-up in children and adults who the vaccine induces antibody responses that persist for at least 20 years [2, 8] . Lower VZV IgG titers were associated with had vaccine-induced immunity. Surveillance studies indicate that breakthrough varicella oclower cellular immune responses in adult vaccinees [5] . However, with longer follow-up, VZV-specific IgG antibody concurs at an incidence of about 2% -3% per year in children and adults but that the incidence and severity do not increase over centrations increased significantly in adults and children. The increase in antibody titers with time after immunization has time [2, 14] . Our finding that immune responses to VZV are preserved well after varicella vaccination is consistent with been observed by others [13] . Our study demonstrated that even among vaccinees with low initial responses, the antibody these clinical observations. Whether the immunologic basis for the increase of VZV concentrations can be expected to increase over time and that the two-dose vaccine regimen is sufficient to achieve longimmune responses in vaccinees was due to endogenous or ex-/ 9d46$$ju46 05-11-98 10:41:02 jinfa UC: J Infect
